<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Moderna, Inc. (NASDAQ:MRNA) shares are picking up momentum after a steep sell-off on Monday, triggered by a scientific publication that suggested booster doses are unwarranted at this point of time. The company released a statement Wednesday that said incremental data from the Phase 3 COVE study suggested waning immunity a year after the first two doses — a supporting argument in favor of a booster dose.
...read full article on Benzinga
